A prospective, multicenter, phase Ⅱ clinical study of concurrent chemotherapy and thoracic three-dimensional radiotherapy for stage IV non-small cell lung cancer -Impact of clinical factors on survival(PPRA-RTOG003)
Teaching and Research Section of Oncology,Guizhou Medical University,Guiyang 550004,China (Du YJ);Department of Radiation Oncology,Gansu Cancer Hospital (Wang XH);Department of Radiation Oncology,Sichuan Cancer Hospital (Li T);Department of Radiation Oncology,Fujian Cancer Hospital (Li JCH);Department of Radiation Oncology,Zhejiang Cancer Hospital (Chen M);Department of Radiation Oncology,West China Hospital of Sichuan University (Lu Y);Department of Thoracic Oncology,Affiliated Cancer Hospital and Affiliated Hospital of Zunyi Medical College (Bai YJ);Department of Oncology,Guizhou Cancer Hospital,Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China (Su SHF,Ouyang WW,Ma ZH,Li QS,Hu YX,Li HQ,Lu B);Stem Cell and Tissue Engineering Research Center,Guizhou Medical University (He ZHX)
Abstract： Objective To investigate the impact of clinical factors on survival in patients receiving concurrent chemotherapy and three-dimensional radiotherapy (3DRT) for stage IV non-small cell lung cancer (NSCLC). Methods A total of 203 patients were enrolled in a prospective clincial study from 2008 to 2012, and among these patients, 178 patients were eligible for analysis of clinical factors. All patients were treated with platinum-based doublets chemotherapy, with a median number of chemotherapy cycles of 4(2-6 cycles) and a median dose of 3DRT of 60.3 Gy (36.0-76.5 Gy).The Kaplan-Meier method was used to calculate overall survival (OS) rates, the log-rank test was used to compare survival rates between groups, and the Cox regression model were used for multivariate analysis. Results The 1-, 2-, and 3-year overall survival rates were 56%, 16%, and 10%, respectively, and the median survival time was 13 months (95% CI=11.500-14.500). The univariate analysis showed that platelet count ≤221×109/L, neutrophil count ≤5.2×109/L, white blood cell count<7×109/L, and improvement in Karnofsky Performance Scale (KPS) after treatment significantly prolonged OS (P=0.000,0.022,0.003, and 0.029), and metastasis to a single organ and hemoglobin≥120 g/L tended to prolong OS (P=0.058 and 0.075). The multivariate analysis showed that white blood cell count<7×109/L, platelet count ≤221×109/L, and improvement in KPS after treatment were beneficial to OS (all P<0.05).Conclusions White blood cell count and platelet count before treatment and KPS after treatment are prognostic factors for patients with stage IV NSCLC receiving concurrent chemotherapy and 3DRT.Clinical Trial Registry ClinicalTrials.gov, registration number:ChiCTRTNC10001026.
Du Yanjun,Wang Xiaohu,Li Tao et al. A prospective, multicenter, phase Ⅱ clinical study of concurrent chemotherapy and thoracic three-dimensional radiotherapy for stage IV non-small cell lung cancer -Impact of clinical factors on survival(PPRA-RTOG003)[J]. Chinese Journal of Radiation Oncology, 2016, 25(10): 1045-1050.
[1] Scagliotti GV,De Marinis F,Rinaldi M,et alPhase Ⅲ randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer[J].J Clin Oncol,2002,20(21):4285-4291.DOI:10.1200/JCO.2002.02.068. [2] 龙金华,卢冰,欧阳伟炜,等.Ⅳ期非小细胞肺癌化疗同期胸部三维放疗的前瞻性临床研究(三)——不同放疗剂量对生存的影响[J].中华放射肿瘤学杂志,2012,21(1):23-26.DOI:10.3760/cma.j.issn.1004-4221.2012.01.008. Long JH,Lu B,Ouyang WW,et al. A prospective study on concurrent chemotherapy and thoracic three-dimensional radiotherapy for stage Ⅳ non-small cell lung cancer (3)-the impact of radiation dose to thoracic primary tumor on survival[J].Chin J Radiat Oncol,2012,21(1):23-26.DOI:10.3760/cma.j.issn.1004-4221.2012.01.008. [3] Su SF,Li T,Lu B,et al. Three-dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage Ⅳ non-small cell lung cancer:results of a multicenter phase 2 study from PPRA-RTOG,China[J].Int J Radiat Oncol Biol Phys,2015 93(4):769-777.DOI:10.1016/j.ijrobp.2015.08.012. [4] Abdallah FCB,Ali GB,Boudaya MS,et al. Treatment and prognosis of advanced stage non-small-cell lung cancer[J].Rev Mal Respir,2014,31(3):214-220.DOI:10.1016/j.rmr.2013.09.002. [5] Gerdan L,Segedin B,Nagy V,et al. Brain metastasis from non-small cell lung cancer (NSCLC):prognostic importance of the number of involved extracranial organs[J].Strahlenther Onkol,2014,190(1):64-67.DOI:10.1007/s00066-013-0439-6. [6] 马筑,卢冰,李涛,等.Ⅳ期NSCLC化疗同期3DRT的前瞻性多中心Ⅱ期临床研究-PPRA-RTOG003[J].中华放射肿瘤学杂志,2015,24(4):359-363.DOI:10.3760/cma.j.issn.1004-4221.2015.04.001. Ma Z,Lu B,Li T,et al. A prospective,multicenter,phase Ⅱ clinical study of three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small-cell lung cancer-PPRA-RTOG003[J].Chin J Radiat Oncol,2015,24(4):359-363.DOI:10.3760/cma.j.issn.1004-4221.2015.04.001. [7] 王刚,卢冰,苏胜发,等.Ⅳ期非小细胞肺癌化疗同期胸部三维放疗的前瞻性临床研究(二)—不同器官转移状态对生存的影响[J].中华放射肿瘤学杂志,2011,20(6):473-477.DOI:10.3760/cma.j.issn.1004-4221.2011.06.007. Wang G,Lu B,Su SF,et al. A prospective study on concurrent chemotherapy and thoracic three-dimensional radiotherapy for stage Ⅳ non-small cell lung cancer (2)-the impact of different metastasis organs on survival[J].Chin J Radiat Oncol,2011,20(6):473-477.DOI:10.3760/cma.j.issn.1004-4221.2011.06.007. [8] 任维维,米登海,李征,等.非小细胞肺癌紫杉醇类联合顺铂同步或序贯放化疗对比的Meta分析[J].中华肿瘤防治杂志,2013,20(5):377-382. Ren WW,Mi DH,Li Z,et al. Docetaxel or Pacfitaxe plus Cisplatin chemotherapy with concurrent radiotherapy versus sequential radiotherapy for non-small cell lung cancer:a Meta analysis[J].Chin J Cancer Prevent Treat,2013,20(5):377-382. [9] Schiller JH,Harrington D,Belani CP,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98.DOI:10.1056/NEJMoa011954. [10] Zhu JF,Cai L,Zhang XW,et al. High plasma fibrinogen concentration and platelet count unfavorably impact survival in non–small cell lung cancer patients with brain metastases[J].Chin J Cancer,2014,33(2):96-104.DOI:10.5732/cjc.012.10307. [11] Chen HT,Tsou HK,Tsai CH,et al. Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway[J].J Cell Physiol,2010,223(3):737-745.DOI:10.1002/jcp.22083. [12] 张平平,孙军伟,卢久琴,等.非小细胞肺癌患者的基线D-二聚体水平与预后的关系[J].中华肿瘤杂志,2013,35(10):747-750.DOI:10.3760/cma.j.issn.0253-3766.2013.10.006. Zhang PP,Sun JW,Lu JQ,et al. Correlation between baseline plasma D-dimer levels and prognosis in patients with non-smal cell lung cancer[J].Chin J Oncol,2013,35(10):747-750.DOI:10.3760/cma.j.issn.0253-3766.2013.10.006. [13] 曹洪明,王旭,肖慧杰,等.高凝状态与肺癌之间的关系[J].临床和实验医学杂志,2013,12(7):553-556.DOI:10.3969/j.issn.1671-4695.2013.07.033. Cao HM,Wang X,Xiao HJ,et al. The relationship between high coagulation state and lung cancer[J].J Clin Exper Med,2013,12(7):553-556.DOI:10.3969/j.issn.1671-4695.2013.07.033. [14] 王学锋,赵维莅,璩斌.肿瘤患者凝血及纤溶分子标志物变化[J].中华检验医学杂志,2000,23(6):331-333.DOI:10.3760/j:issn:1009-9158.2000.06.003. Wang XF,Zhao WL,Qu B.Changes of coagulation and fibrinolysis molecular markers in patients with cancer[J].Chin J Labor Med,2000,23(6):331-333.DOI:10.3760/j:issn:1009-9158.2000.06.003. [15] Zahorec R.Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill[J].Bratisl Lek Listy,2001,102(1):5-14. [16] Mantovani A,Allavena P,Sica A,et al. Cancer-related inflammation[J].Nature,2008,454(7302):436-444.DOI:10.1038/nature07205. [17] Jafri SH,Shi RH,Mills G.Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC):a retrospective review[J].BMC Cancer,2013,13(1):158.DOI:10.1186/1471-2407-13-158. [18] Rao HL,Chen JW,Li M,et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients′ adverse prognosis[J/OL].PLoS One,2012,7(1):e30806.DOI:10.1371/journal.pone.0030806. [19] 唐小凤,张琳,李疆.治疗前血中性粒细胞数目和白蛋白水平预测鼻咽癌预后的临床意义[J].中国肿瘤临床,2013,40(21):1309-1313.DOI:10.3969/j.issn.1000-8179.20130875. Tang XF,Zhang L,Li J.Clinical significance of neutrophil and albumin pretreatments in nasopharyngeal carcinoma prognosis[J].Chin J Clin Oncol,2013,40(21):1309-1313.DOI:10.3969/j.issn.1000-8179.20130875. [20] 李娜,李芳,顾其华,等.白细胞数量稳定性与NSCLC患者化疗预后相关性研究[J].中华肿瘤防治杂志,2012,19(19):1499-1502. Li N,Li F,Gu QH,et al. Impact of leukocyte on the prognosis of the patients with advanced non-small cell lung cancer[J].Chin J Cancer Prevent Treat,2012,19(19):1499-1502. [21] Van Belle SJP,Cocquyt V.Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy[J].Crit Rev Oncol/Hematol,2003,47(1):1-11.DOI:10.1016/S1040-8428(03)00093-3. [22] Shasha D.The negative impact of anemia on radiotherapy and chemoradiation outcomes[J].Semin Hematol,2001,38(S7):8-15.DOI:10.1016/S0037-1963(01)90125-8. [23] Capuano G,Pavese I,Satta F,et al. Pretreatment correlation between hemoglobin,unintentional weight loss,and inflammatory status in patient with advanced non-small cell lung cancer (NSCLC)[J].J Clin Oncol,2009,27(S15):e20718. [24] Tomita M,Shimizu T,Hara M,et al. Impact of preoperative hemoglobin level on survival of non-small cell lung cancer patients[J].Anticanc Res,2008,28(3B):1947-1950. [25] 苏胜发,卢冰,胡银祥,等.NSCLC单器官转移化疗同期原发及转移灶放疗的临床观察[J].中华肿瘤防治杂志,2013,20(14):1102-1105. Su SF,Lu B,Hu YX,et al. Survival in patients with non-small cell lung cancer and single organ metastasis treated with thoracic concurrent chemoradiotherapy and metastatic lesions radiotherapy[J].Chin J Cancer Prevent Treat,2013,20(14):1102-1105. [26] Parikh RB,Cronin AM,Kozono DE,et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2014,89(4):880-887.DOI:10.1016/j.ijrobp.2014.04.007. [27] Hollen PJ,Gralla RJ,Stewart JA,et al. A prospective comparison of Karnofsky (KPS) with ECOG performance status in patients with non-small cell lung cancer (NSCLC):a COMET group study investigating sensitivity and specificity issues important in clinical decision making[J].J Clin Oncol,2005,23(16):8134.
2016, Vol. 25 
